Company news

Alkermes plc news in 2025

Alkermes plc's news releases, calls and decks from 2025, newest first.

View company

Alkermes to Present at the 44th Annual J.P. Morgan Healthcare Conference

December 29, 2025

Alkermes to Participate in Two Upcoming Investor Conferences

November 24, 2025

Alkermes plc Announces Increased Offer to Acquire Avadel Pharmaceuticals plc

November 18, 2025

Alkermes Response to Avadel Announcement

November 13, 2025

Alkermes Announces Positive Topline Results From Vibrance-2 Phase 2 Study of Once-Daily Alixorexton in Patients With Narcolepsy Type 2

November 11, 2025

FORM 8.1(a) & (b) (Opening Position Disclosure)

November 5, 2025

Avadel Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Corporate Update

November 4, 2025

Alkermes plc Reports Third Quarter 2025 Financial Results

October 27, 2025

Alkermes plc Announces Agreement to Acquire Avadel Pharmaceuticals plc

October 21, 2025

Alkermes to Report Third Quarter Financial Results on October 28, 2025

October 19, 2025

Alkermes Appoints Joshua Reed as Chief Financial Officer

September 11, 2025

Alkermes Announces Launch of 8th Annual Alkermes Pathways Research Awards® Program

September 10, 2025

Alkermes Presents Detailed Positive Results from Vibrance-1 Phase 2 Study of Alixorexton in Patients with Narcolepsy Type 1 at World Sleep Congress 2025

September 6, 2025

Alkermes to Present Detailed Positive Results From Vibrance-1 Phase 2 Study Evaluating Alixorexton in Patients With Narcolepsy Type 1 at World Sleep 2025

August 24, 2025

National Veterinary Associates Welcomes Brian McKeon to Board of Directors

August 18, 2025

Alkermes plc Reports Second Quarter 2025 Financial Results

July 28, 2025

Alkermes Announces Positive Topline Results From Vibrance-1 Phase 2 Study of Once-Daily Alixorexton in Patients With Narcolepsy Type 1

July 20, 2025

Alkermes to Report Second Quarter Financial Results on July 29, 2025

July 14, 2025

Alkermes to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference

June 1, 2025

Alkermes Highlights Data From Psychiatry Portfolio at Spring 2025 Scientific Conferences

June 1, 2025

Alkermes to Present New Research Related to ALKS 2680 at SLEEP 2025

May 28, 2025

Alkermes plc Reports First Quarter 2025 Financial Results

April 30, 2025

New Survey Provides Insights into Diagnosis and Treatment Journey for People Living With Alcohol Use Disorder (AUD)

April 30, 2025

Alkermes to Report First Quarter Financial Results on May 1, 2025

April 16, 2025

Alkermes to Participate in the 24th Annual Needham Virtual Healthcare Conference

April 1, 2025

Alkermes Announces Initiation of Vibrance-3 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Idiopathic Hypersomnia

March 31, 2025

New National Survey of Healthcare Providers Offers Insights Into the Dynamic and Challenging Treatment Journey for People Living With Schizophrenia or Bipolar I Disorder

March 27, 2025

Alkermes to Participate in Upcoming Investor Conferences

February 25, 2025

Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2024 and Provides Financial Expectations for 2025

February 11, 2025

Alkermes to Report Fourth Quarter and Year-End Financial Results on Feb. 12, 2025

February 4, 2025

Alkermes to Present at the 43rd Annual J.P. Morgan Healthcare Conference

January 1, 2025

Calls in 2025

Decks in 2025